WallStreetZenWallStreetZen

NASDAQ: JBIO
Jade Biosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for JBIO

Based on 2 analysts offering 12 month price targets for Jade Biosciences Inc

Min Forecast
$14.00+103.19%
Avg Forecast
$15.50+124.96%
Max Forecast
$17.00+146.73%

Should I buy or sell JBIO stock?

Based on 2 analysts offering ratings for Jade Biosciences Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although JBIO's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates JBIO as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their JBIO stock forecasts and price targets.

JBIO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-06-16
lockedlocked$00.00+00.00%2025-05-15

1 of 1

Forecast return on equity

Is JBIO forecast to generate an efficient return?

Company
-2.1%
Industry
135.39%
Market
89.2%
JBIO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is JBIO forecast to generate an efficient return on assets?

Company
-2.03%
Industry
46.95%
JBIO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

JBIO earnings per share forecast

What is JBIO's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$2.85
Avg 2 year Forecast
-$1.93
Avg 3 year Forecast
-$1.92

JBIO revenue forecast

What is JBIO's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$18.5M

JBIO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
JBIO$6.89$15.50+124.96%Strong Buy
NLSP$1.80N/AN/A
ARTL$10.20$25.00+145.10%Strong Buy
CANF$0.66$10.00+1,424.39%Strong Buy
VYNE$0.35$4.50+1,174.79%Buy
View Top Biotech Stocks

Jade Biosciences Stock Forecast FAQ

Is Jade Biosciences Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: JBIO) stock is to Strong Buy JBIO stock.

Out of 2 analysts, 1 (50%) are recommending JBIO as a Strong Buy, 1 (50%) are recommending JBIO as a Buy, 0 (0%) are recommending JBIO as a Hold, 0 (0%) are recommending JBIO as a Sell, and 0 (0%) are recommending JBIO as a Strong Sell.

If you're new to stock investing, here's how to buy Jade Biosciences stock.

What is JBIO's earnings growth forecast for 2025-2027?

(NASDAQ: JBIO) Jade Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.68%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.37%.

Jade Biosciences's earnings in 2025 is -$48,960,000.On average, 3 Wall Street analysts forecast JBIO's earnings for 2025 to be -$2,360,208, with the lowest JBIO earnings forecast at -$2,558,962, and the highest JBIO earnings forecast at -$1,995,825. On average, 4 Wall Street analysts forecast JBIO's earnings for 2026 to be -$1,596,246, with the lowest JBIO earnings forecast at -$1,780,507, and the highest JBIO earnings forecast at -$1,382,999.

In 2027, JBIO is forecast to generate -$1,585,894 in earnings, with the lowest earnings forecast at -$1,879,885 and the highest earnings forecast at -$1,291,903.

What is JBIO's revenue growth forecast for 2031-2031?

(NASDAQ: JBIO) Jade Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.53%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.03%.

Jade Biosciences's revenue in 2025 is $0.

In 2031, JBIO is forecast to generate $15,295,801 in revenue, with the lowest revenue forecast at $15,295,801 and the highest revenue forecast at $15,295,801.

What is JBIO's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: JBIO) forecast ROA is -2.03%, which is lower than the forecast US Biotechnology industry average of 46.95%.

What is JBIO's Price Target?

According to 2 Wall Street analysts that have issued a 1 year JBIO price target, the average JBIO price target is $15.50, with the highest JBIO stock price forecast at $17.00 and the lowest JBIO stock price forecast at $14.00.

On average, Wall Street analysts predict that Jade Biosciences's share price could reach $15.50 by Jun 16, 2026. The average Jade Biosciences stock price prediction forecasts a potential upside of 124.96% from the current JBIO share price of $6.89.

What is JBIO's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: JBIO) Jade Biosciences's current Earnings Per Share (EPS) is -$59.50. On average, analysts forecast that JBIO's EPS will be -$2.85 for 2025, with the lowest EPS forecast at -$3.09, and the highest EPS forecast at -$2.41. On average, analysts forecast that JBIO's EPS will be -$1.93 for 2026, with the lowest EPS forecast at -$2.15, and the highest EPS forecast at -$1.67. In 2027, JBIO's EPS is forecast to hit -$1.92 (min: -$2.27, max: -$1.56).

What is JBIO's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: JBIO) forecast ROE is -2.1%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.